Trading Signals: PRNB Stock Price Prediction and Forecast (Fri. Sep. 14, 2018 - Fri. Sep. 25, 2020)(Principia Biopharma Inc)
| PRNB latest price $100.0300 (0.06%) ($99.9500 - $100.3700) on Fri. Oct. 2, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.63% (three month average) | RSI | 52 | Latest Price | $100.0300(0.06%) | Stocks Behave Similarly | Similar Stock List | Market Behavior | Growth stock sell-off for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support PRNB advance at 0% a week (0% probability) XBI(50%) VWO(33%) GDXJ(-59%) SLV(-152%) (0%) | Factors Impacting PRNB price | PRNB will decline at least -1.815% in a week (0% probabilities). GDXJ(-59%) VWO(33%) XBI(50%) IPO(158%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.815% (StdDev 3.63%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $99.99(0.04%) | 10 Day Moving Average | $100.01(0.02%) | 20 Day Moving Average | $100.02(0.01%) | To recent high | -1% | To recent low | 78.6% | Market Cap | $N/A | | | | Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. |